Nicox announced that additional data on NCX 470 was presented at the 10th World Glaucoma Congress (WGC) held from June 28 to July 1, 2023 in Rome, Italy. NCX 470 is a new nitric oxide (NO)-donating bimatoprost eye drops in phase 3 clinical development for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The first Phase 3 Mont Blanc study, a randomized, double-blind, multicenter, parallel-group study conducted in the United States comparing NCX 470 (0.1%) to latanoprost (0.005%), was completed in October 2022. The second phase 3 Denali study, which has a protocol similar to that of the Mont Blanc study, and which also includes a long-term safety study, is ongoing. The schedule of Phase 3b clinical studies to evaluate the dual mechanism of action (nitric oxide and prostaglandin analogue) in lowering IOP and the potential beneficial effects of NCX 470 on the retina is currently under review. The press release on the second quarter results will provide additional information in this regard.